Compare Ginkgo Bioworks Holdings Inc (DNA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Orion Office REIT Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.98 (market cap $590.53M), while Orion Office REIT Inc trades at $2.67 (market cap $151.17M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 3.9× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.01% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | ONL | |
|---|---|---|
Market Cap | $590.53M | $151.17M |
Sector | Health | Real Estate |
52-Week High | $16.14 | $3.04 |
52-Week Low | $5.48 | $1.93 |
Enterprise Value | $627.78M | $634.82M |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
ONL trades at $2.72, down 1.09% today, with a bearish technical signal and negative earnings momentum. The company reported Q1 2026 EPS of -$0.24, missing expectations, while revenue declined to $147.65M in 2025. Despite a low P/B of 0.25, profitability remains weak with a -98.36% net margin. Recent news highlights strategic reviews and portfolio repositioning toward dedicated-use assets.
The outlook is cautious due to persistent losses and declining revenue, though strategic asset sales and debt management provide some stability. Risks include high leverage and office market challenges. Analyst sentiment is mixed with 50% buy ratings. Investment opportunity hinges on successful execution of strategic initiatives amid a difficult operating environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
